Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study
暂无分享,去创建一个
P. Sonneveld | M. Béné | P. Moreau | F. Magrangeas | S. Minvielle | H. Avet-Loiseau | B. Jamet | C. Bailly | C. Bodet-Milin | C. Touzeau | F. Kraeber-Bodéré | T. Carlier | J. Corre | H. Caillon | M. van Duin | S. Wuillème | M. Chérel | Jean-Baptiste Alberge | T. Kampfenkel
[1] C. Nanni,et al. Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials , 2020, Cancers.
[2] P. Moreau,et al. FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients? , 2020, Cancers.
[3] P. Sonneveld,et al. Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study , 2019, Blood.
[4] P. Sonneveld,et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.
[5] D. Auclair,et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis , 2019, Nature Communications.
[6] Hiroki Kobayashi,et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Pingping Qu,et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis , 2018, Leukemia.
[8] M. Wuest,et al. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer—effects of hypoxia , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] O. Stephens,et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing , 2017, Nature Communications.
[10] Caleb K. Stein,et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.
[11] Bart Barlogie,et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.
[12] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[13] S. Iwata,et al. Structure and mechanism of the mammalian fructose transporter GLUT5 , 2015, Nature.
[14] B. Barlogie,et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.
[15] P. Sonneveld,et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.
[16] Cheng Li,et al. Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[19] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[20] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.